Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28019387 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAOBBCHEAOC3ABCB1 | |
| SCHEMBL719263 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAOBBCHEAOC3ABCB1 | |
| SCHEMBL11810281 | 0.91 | OPRK1 (0.41) | ALDH1A1MAOBBCHEMAOATRPM8 | |
| Hydrochloric Acid SCHEMBL11818993 | 0.90 | OPRD1 (0.40) | ALDH1A1MAOBBCHEMAOATRPM8 | |
| SCHEMBL11820982 | 0.90 | SLC1A5 (0.39) | ALDH1A1MAOBBCHEMAOAPOLB | |
| SCHEMBL7245309 | 0.90 | OPRD1 (0.39) | ALDH1A1MAOBAOC3ABCB1TSHR | |
| SCHEMBL7245302 | 0.90 | OPRD1 (0.39) | ALDH1A1MAOBAOC3ABCB1TSHR | |
| SCHEMBL3799821 | 0.90 | ALDH1A1 (0.40) | ALDH1A1MAOBBCHEAOC3ABCB1 | |
| SCHEMBL16503716 | 0.90 | ALDH1A1 (0.39) | ALDH1A1MAOBAOC3TSHRNPC1 | |
| SCHEMBL11181213 | 0.89 | ABCB1 (0.42) | ALDH1A1MAOBBCHEABCB1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104655786-B | Method for separating and measuring formoterol intermediate related substances by liquid chromatography | 北京万全德众医药生物技术有限公司 | 2020-06-23 | — | — | CN | disclosed |
| CN-104655786-A | Method for measuring substances related to formoterol intermediate by separation of liquid chromatography | BEIJING VENTUREPHARM BIOTECH CORP | 2015-05-27 | — | — | CN | disclosed |
| CN-104655786-A | Method for measuring substances related to formoterol intermediate by separation of liquid chromatography | BEIJING VENTUREPHARM BIOTECH CORP | 2015-05-27 | — | — | CN | disclosed |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-03-01 | — | — | US | disclosed |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | disclosed |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | disclosed |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-12-22 | — | — | US | disclosed |
| WO-2010128355-A2 | IMPROVED PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128355-A2 | IMPROVED PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2010-11-11 | — | — | WO | disclosed |
| JP-2000239237-A | CRYSTAL OF OPTICALLY ACTIVE COMPOUND AND ITS PRODUCTION | YAMANOUCHI PHARMACEUT CO LTD | 2000-09-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ADRB1, ADRB2, ADRA1A | ALDH1A1 1084/4885MAOB 391/4885BCHE 3767/4885 |
| US-20110313199-A1 | PROCESSES FOR PREPARING SUBSTANTIALLY PURE ARFORMOTEROL AND ITS INTERMEDIATES | ADRB2, ADRA2A, ADRB1 | ALDH1A1 1401/4885MAOB 983/4885BCHE 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.